Program
Anti-DLL3 Antibody-drug Conjugate FZ-AD005
Its studies are mostly in Glioblastoma · Small Cell Lung Carcinoma, led by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical.
Furthest: phase 1, since May 12, 20242 company-led studies, 2 open or runningNext primary completion: Dec 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | 22 open or running | phase 1since May 12, 2024 | May 12, 2024 | Dec 1, 2027phase 1 · NCT07455045 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2024First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT06424665 · 162 planned · China
- Mar 2, 2026Phase 1 study in GliomaNCT07455045 · 40 planned · China
Ahead
- Dec 1, 2027Primary completion: phase 1 study in GliomaNCT07455045
TargetBeta
DLL3 →read by rule
“An antibody-drug conjugate (ADC) composed of FZ-A038, a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), ”NCIt, by rule
Other programs on DLL3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| Zocilurtatug Pelitecanrule | Zai Lab | phase 3 | 6 |
| Anti-DLL3 Antibody-drug Conjugate BL-M14D1 | Sichuan Biokin Pharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Autologous Anti-DLL3 CAR-T Cells DJI136 | Novartis | phase 2 | 2 |
| Anti-DLL3 Antibody-drug Conjugate IDE849 | ideaya-biosciences | phase 2 | 2 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Actinium Ac 225-ABD147rule | abdera-therapeutics-inc | phase 1 | 1 |
| Indium In 111-ETN029 | Novartis | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07455045Glioma · China | 1 | Not yet recruiting | Dec 1, 2027 | 40 |
| NCT06424665Small Cell Lung Carcinoma · China | 1 | Recruiting | Aug 1, 2026 | 162 |
How it is read
Names in the registry
- “FZ-AD005”, 2 entries
Conditions, from the studies’ own filings
- Glioblastoma, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.